Atea Pharmaceuticals posted a net loss in Q3 2025, driven by increased R&D expenses tied to its HCV clinical development. Despite the financial loss, progress continued on its global Phase 3 program, and the company expanded its pipeline with a new hepatitis E virus (HEV) program.

Atea Pharmaceuticals reported a net loss of $34.272 million for Q1 2025, an improvement from a $63.169 million loss in Q1 2024. The company is making significant progress in its Phase 3 clinical trials for HCV treatment, with ongoing enrollment in C-BEYOND and expected mid-year initiation for C-FORWARD. Cash and cash equivalents stood at $425.436 million.

Atea Pharmaceuticals reported a net loss of $33.54 million for Q4 2024, with total operating expenses of $39.03 million. The company held $454.72 million in cash, cash equivalents, and marketable securities at the end of the quarter. Research and development expenses were $25.67 million, while general and administrative expenses reached $13.36 million.

Atea Pharmaceuticals reported its third quarter 2024 financial results, highlighting progress in its HCV program with the combination of bemnifosbuvir and ruzasvir. Topline results from the Phase 2 combination study are expected in early December, with a Phase 3 program planned for early next year. The company had $482.8 million in cash, cash equivalents, and marketable securities as of September 30, 2024.

Atea Pharmaceuticals reported its second quarter 2024 financial results, highlighting the completion of patient enrollment in the global Phase 3 SUNRISE-3 study of bemnifosbuvir for COVID-19 and the global Phase 2 study evaluating the combination of bemnifosbuvir and ruzasvir in HCV-infected patients. The company's cash, cash equivalents, and marketable securities totaled $502.2 million as of June 30, 2024. Research and development expenses increased due to the advancement of both clinical trials.

Atea Pharmaceuticals reported its financial results for Q1 2024, highlighting the completion of enrollment in the Phase 3 SUNRISE-3 trial for COVID-19 treatment and advancements in the Phase 2 HCV study. The company's cash, cash equivalents, and marketable securities totaled $541.5 million.

Atea Pharmaceuticals reported its Q4 and full year 2023 financial results, highlighting the rapid enrollment in their Phase 2 HCV combination study and the Phase 3 SUNRISE-3 study. The final results from the lead-in cohort of the Phase 2 combination study confirmed a 98% SVR4 rate. Patient enrollment for SUNRISE-3 has surpassed 1,400 patients, triggering the second interim analysis.

Atea Pharmaceuticals reported its Q3 2023 financial results, highlighting the ongoing Phase 3 SUNRISE-3 trial for COVID-19 and the Phase 2 trial for hepatitis C (HCV). Patient enrollment continues in the SUNRISE-3 trial, with the first interim analysis expected in Q1 2024. The Phase 2 HCV trial has completed enrollment of the 60-patient lead-in cohort, and initial results are expected in early 2024. The company's cash, cash equivalents, and marketable securities totaled $595.1 million as of September 30, 2023.

Atea Pharmaceuticals reported their Q2 2023 financial results, highlighting the continued advancement of the Phase 3 SUNRISE-3 trial for COVID-19 and the progress of their Phase 2 combination study for Hepatitis C.

Atea Pharmaceuticals reported first quarter results, highlighting the advancement of clinical trials and R&D efforts, including the continued enrollment in the Phase 3 SUNRISE-3 trial for COVID-19 and the upcoming Phase 2 trial for HCV treatment.

Atea Pharmaceuticals reported its fourth quarter and full year 2022 financial results, highlighting progress in its clinical development programs, particularly for bemnifosbuvir in COVID-19 and HCV treatments. The company is focusing resources on COVID-19 and HCV programs, and has deprioritized the dengue program.

Atea Pharmaceuticals reported on their progress in advancing clinical candidates, with expectations of pivotal developments in 2023. They anticipate imminent enrollment into the SUNRISE-3 trial for COVID-19, completion of enrollment in the AT-752 challenge study and the first cohort of DEFEND-2, and submission of clinical trial applications for a Hepatitis C study.

Atea Pharmaceuticals reported a net loss of $31.3 million for the second quarter ended June 30, 2022, compared to a net income of $1.5 million for the quarter ended June 30, 2021. The company had $684.5 million in cash and cash equivalents as of June 30, 2022.

Atea Pharmaceuticals reported a net loss of $42.1 million for the first quarter of 2022, compared to a net income of $30.7 million for the same period in 2021. The company highlighted new bemnifosbuvir data showing clinical benefits in two placebo-controlled trials and the initiation of a Phase 2 global study and human challenge trial with AT-752 for dengue.

Atea Pharmaceuticals reported fourth quarter collaboration revenue of $192.2 million and net income of $117.1 million. The company is advancing three Phase 2 programs in COVID-19, HCV, and dengue fever.

Atea Pharmaceuticals reported a net loss of $28.2 million for Q3 2021, with collaboration revenue of $32.8 million driven by the Roche License Agreement. The company is focusing on the development of AT-527, with ongoing Phase 3 trials and protocol amendments to improve trial outcomes. New data supports AT-527's antiviral activity against COVID-19 variants.

Atea Pharmaceuticals reported a net income of $1.5 million for the second quarter of 2021, a significant increase compared to the net loss of $10.0 million in the same quarter of the previous year. The company's collaboration revenue reached $60.4 million due to the Roche License Agreement, and there was progress in the clinical development of AT-527 for COVID-19 treatment.

Atea Pharmaceuticals reported a net income of $30.7 million for the quarter ended March 31, 2021, compared to a net loss of $4.0 million for the quarter ended March 31, 2020. The increase in net income was primarily due to the recognition of collaboration revenue related to the Roche License Agreement in the amount of $66.0 million.